Barbara J. Ring - Concepedia

Author

Barbara J. Ring

Eli Lilly (United States)

Also Known As

B J Ring, B RING, B Ring, BARBARA J. RING, Barbara J Ring, Barbara J. Ring, Barbara Ring, Ring, B

Publications

5.7K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Medical College of Wisconsin GlaxoSmithKline (United States)Janssen (Belgium)Bristol-Myers Squibb (United States)

About

Barbara J. Ring is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	1.4K
2	Health Sciences	2	2	390
3	Natural Sciences	2	2	119
4	Public Health	1	1	15
5	Social Sciences	1	1	20

Barbara J. Ring

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7 J. Andrew Williams, Barbara J. Ring, Varon E. Cantrell, Drug Metabolism and Disposition	2002	463
Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression Vishal Lamba, Jatinder K. Lamba, Kazuto Yasuda, Journal of Pharmacology and Experimental Therapeutics	2003	400
Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. Regina M. Housley, Charles F. Morris, W Boyle, Journal of Clinical Investigation Rat Gastrointestinal TractGastroenterologyPathologyCell ProliferationInflammation	1994	272
INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450 Jessica Rehmel, James A. Eckstein, Nagy A. Farid, Drug Metabolism and Disposition	2006	263
Identification of a polymorphically expressed member of the human cytochrome P-450III family. Steven Wrighton, Barbara J. Ring, Paul B. Watkins, Molecular Pharmacology	1989	227
Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. Barbara J. Ring, John T. Catlow, Thomas J. Lindsay, Journal of Pharmacology and Experimental Therapeutics	1996	214
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance Barbara J. Ring, Jenny Y. Chien, Kimberly K. Adkison, Journal of Pharmaceutical Sciences Pharmacokinetic ModelingMedicineDrug DiscoveryPrediction MethodsPhrma Cpcdc Initiative	2011	198
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach Patrick Poulin, Rhys D.O. Jones, Hannah M. Jones, Journal of Pharmaceutical Sciences Precision DosingPhysiologically Based PharmacokineticsPharmacokinetic ModelingHuman PharmacokineticsMedicine	2011	170
Differential Modulation of UDP-Glucuronosyltransferase 1A1 (UGT1A1)-Catalyzed Estradiol-3-glucuronidation by the Addition of UGT1A1 Substrates and Other Compounds to Human Liver Microsomes J. Andrew Williams, Barbara J. Ring, Varon E. Cantrell, Drug Metabolism and Disposition	2002	150
THE EFFECT OF INCUBATION CONDITIONS ON THE ENZYME KINETICS OF UDP-GLUCURONOSYLTRANSFERASES Matthew G. Soars, Barbara J. Ring, Steven Wrighton Drug Metabolism and Disposition	2003	150

Page 1